Dymon Asia Capital (Singapore)’s AstraZeneca AZN Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.69M	Buy	30,000 +12,000	+67%	+$2.26M	0.24%	62
2026 Q1	$3.55M	Buy	18,000 +7,300	+68%	+$1.41M	0.36%	80
2025 Q4	$1.97M	Buy	10,700 +700	+7%	+$123K	0.19%	102
2025 Q3	$1.53M	Hold	10,000	–	–	0.16%	135
2025 Q2	$1.4M	Sell	10,000 -1,000	-9%	-$140K	0.19%	97
2025 Q1	$1.62M	Buy	11,000 +3,000	+38%	+$434K	0.36%	68
2024 Q4	$1.05M	Buy	+8,000	New	+$1.12M	0.24%	72

Other funds holding AZN

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s AZN Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) increased its AstraZeneca (AZN) stake by 67% in Q2 2026, buying an estimated $2.26M and bringing the position to 30,000 shares worth $5.69M. The position accounts for 0.24% of the portfolio, ranked #62.

Dymon Asia Capital (Singapore) first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. 796 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Dymon Asia Capital (Singapore) held 30,000 shares of AstraZeneca worth $5.69M as of Q2 2026.
Dymon Asia Capital (Singapore) bought 12,000 AstraZeneca shares in Q2 2026, an estimated $2.26M.
AstraZeneca made up 0.24% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #62 holding.
Dymon Asia Capital (Singapore) first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
796 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.